TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25654524

Group type: EXPERIMENTAL
Intervention: Integration of health protection and health promotion with a continuous improvement system (Kaizen)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study: 23409693

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 40
Study: 20530001

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stents
Number of subjects: 705

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 705

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 705
Study: 18702660

Group type: EXPERIMENTAL
Intervention: EC‐MPS (1080 mg bid)
Number of subjects: 154

Group type: COMPARATOR
Intervention: MMF (1500 mg bid)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: EC‐MPS
Number of subjects: 154

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 154
Study: 16880774

Group type: EXPERIMENTAL
Intervention: GHB (2‐18 g/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 and 1 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pentobarbital (200 and 400 mg/70 kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12761014

Group type: EXPERIMENTAL
Intervention: Labor epidural analgesia
Number of subjects: 0
Study: 10999559

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Low stimulation (active-control group)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High stimulation
Number of subjects: 195
Study: 9314121

Group type: EXPERIMENTAL
Intervention: Diagnosis of psychosis
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: History of trauma
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Anti-HCV detection
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Viraemia and genotype distribution
Number of subjects: 1180
Study: 8380634

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Vindesine (VDS; 3 mg/m2 on days 1 and 8)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Mitomycin C (MMC; 8 mg/m2 on days 1 and 8)
Number of subjects: 76
Study: 2427846

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 19
Study: 30236087

Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy with Silicone tubes and Ologen implants (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dacryocystorhinostomy with Silicone tubes (Group A)
Number of subjects: 60
Study: 28317354

Group type: EXPERIMENTAL
Intervention: Improved appliance FR III
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classic appliance FR III
Number of subjects: 40
Study: 23467836

Group type: EXPERIMENTAL
Intervention: 5-session group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10-session group
Number of subjects: 26
Study: 22777936

Group type: EXPERIMENTAL
Intervention: Fosinopril (2-year angiotensin-converting enzyme inhibition)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Visit-to-visit blood pressure variability assessment
Number of subjects: 397
Study: 21107100

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Surgical resection (RES)
Number of subjects: 230
Study: 18387854

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 40
Study: 15735611

Group type: EXPERIMENTAL
Intervention: Grapefruit juice 300 mL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grapefruit juice 1200 mL
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 12824095

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex‐warfarin users
Number of subjects: 0
Study: 10810938

Group type: EXPERIMENTAL
Intervention: Acuvue
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gentle Touch
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Frequency 38
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Proclear
Number of subjects: 6
Study: 8856481

Group type: EXPERIMENTAL
Intervention: LRB081 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LRB081 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LRB081 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LRB081
Number of subjects: 8
Study: 1732347

Group type: EXPERIMENTAL
Intervention: Urokinase (4,400 U/kg as an intravenous bolus infusion, then 4,400 U/kg per h over 12 h; n = 29)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Alteplase (10 mg as an intravenous bolus infusion, then 90 mg over 2 h; n = 34)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 63

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 63
Study: 6374263

Group type: EXPERIMENTAL
Intervention: Pindolol eye drops 1%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Timolol eye drops 0.5%
Number of subjects: 41
Study: 29901560

Group type: EXPERIMENTAL
Intervention: DFCI 00-01 protocol
Number of subjects: 4

Group type: COMPARATOR
Intervention: DFCI 95-01 protocol
Number of subjects: 4

Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 4
Study: 26202320

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Graphic pictorial warnings
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Symbolic pictorial warnings
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Testimonial pictorial warnings
Number of subjects: 2083
Study: 24269645

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 40
Study: 22242700

Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 21
Study: 20718911

Group type: EXPERIMENTAL
Intervention: Diagnostic performance measures
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 8
Study: 19101390

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (n=937)
Number of subjects: 1858

Group type: COMPARATOR
Intervention: Placebo (n=921)
Number of subjects: 1858
Study: 15638890

Group type: EXPERIMENTAL
Intervention: T2N0M0 group (n=21)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: T3aN0M0 group (n=97)
Number of subjects: 118
Study: 12416659

Group type: EXPERIMENTAL
Intervention: IBI/S (silybin-beta-cyclodextrin) 135 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9682116

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECCE with continuous curvilinear capsulorhexis (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECCE with letter‐box capsulotomy (Group 3)
Number of subjects: 60
Study: 8595515

Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 0
Study: 2576261

Group type: EXPERIMENTAL
Intervention: OC containing 75 micrograms gestodene (GTD) and 30 micrograms ethinyl estradiol (EE)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: OC with 150 micrograms desogestrel (DSG) and 30 micrograms EE
Number of subjects: 49
Study: 792404

Group type: EXPERIMENTAL
Intervention: Estolate suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethyl succinate suspension
Number of subjects: 0
Study: 31430545

Group type: EXPERIMENTAL
Intervention: Breath awareness meditation
Number of subjects: 1

Group type: COMPARATOR
Intervention: Active control task
Number of subjects: 1
Study: 28557589

Group type: EXPERIMENTAL
Intervention: Hydroimplantation technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 26391621

Group type: EXPERIMENTAL
Intervention: Cogmed working memory program (intervention group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waitlist-control (control group)
Number of subjects: 77
Study: 23352760

Group type: EXPERIMENTAL
Intervention: Morphine treatment (10 μg/kg/h during the neonatal period)
Number of subjects: 0
Study: 21070193

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual hospital-based rehabilitation program (Control)
Number of subjects: 118
Study: 19736510

Group type: EXPERIMENTAL
Intervention: EC‐‐>DOC (4x epirubicin/cyclophosphamide; 4x docetaxel)
Number of subjects: 110

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, Fluorouracil)
Number of subjects: 110
Study: 16682304

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 10398579

Group type: EXPERIMENTAL
Intervention: ThinPrep preparations
Number of subjects: 473

Group type: COMPARATOR
Intervention: Conventional Pap smears
Number of subjects: 473
Study: 8656444

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus tamoxifen (n = 38)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Radiotherapy alone (n = 46)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Tamoxifen with radiotherapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Total radiation dose
Number of subjects: 196
Study: 1854047

Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg.kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Etomidate (0.5 mg.kg‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (Thiopentone and Etomidate)
Number of subjects: 16
Study: 6217961

Group type: EXPERIMENTAL
Intervention: Percutaneous blind liver biopsy (PB)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Laparoscopy with guided biopsy (LB)
Number of subjects: 126
Study: 31701432

Group type: EXPERIMENTAL
Intervention: 24-hour recall with reminders
Number of subjects: 2400

Group type: COMPARATOR
Intervention: No recall period (standard PROMIS administration)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: 7-day recall
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 2400
Study: 29181852

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Eleview®
Number of subjects: 5
Study: 28965380

Group type: EXPERIMENTAL
Intervention: Inlaid labial mucosal graft repair (LMGR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bladder mucosal graft repair (BMGR)
Number of subjects: 55
Study: 24225449

Group type: EXPERIMENTAL
Intervention: SFA-rich diet (18% energy)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (10% energy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no specific control diet mentioned)
Number of subjects: 24
Study: 22236931

Group type: EXPERIMENTAL
Intervention: Varenicline for 8 weeks
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 272

Group type: COMPARATOR
Intervention: Brief counselling (Control Group 1)
Number of subjects: 272
Study: 20609435

Group type: EXPERIMENTAL
Intervention: EX/RP+MI
Number of subjects: 30

Group type: COMPARATOR
Intervention: EX/RP
Number of subjects: 30
Study: 17906192

Group type: EXPERIMENTAL
Intervention: EGCG (300 mg/d for 2 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16140426

Group type: EXPERIMENTAL
Intervention: 2 cans/day of a protein and energy dense oral nutrition supplement +/− n-3 fatty acids
Number of subjects: 200

Group type: COMPARATOR
Intervention: Noncompliant patients (less than 1.5 cans/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Compliant patients (1.5 cans/day or more)
Number of subjects: 200
Study: 12153743

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10440564

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including six components: (1) mailing of six practice recommendations in a CME course; (2) mailing of supplementary practice-based tools; (3) follow-up mailings reinforcing recommendations; (4) invitation to an AAN-sponsored seminar; (5) endorsement by opinion leaders; (6) specialty-society sponsorship and endorsement.
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 417

Group type: COMPARATOR
Intervention: Baseline group (not specified in detail).
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention.
Number of subjects: 417
Study: 7751491

Group type: EXPERIMENTAL
Intervention: Extended Relationship Enhancement (ERE)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Brief Broad‐spectrum (BBS)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Extended Cognitive‐Behavioral (ECB)
Number of subjects: 188
Study: 2138489

Group type: EXPERIMENTAL
Intervention: Doxacurium (initial dose of 25 micrograms kg‐1, with incremental doses of 5 micrograms kg‐1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.08 mg kg‐1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Edrophonium (1.0 mg kg‐1)
Number of subjects: 35
Study: 28746243

Group type: EXPERIMENTAL
Intervention: Barbell hip thrust strength training (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 21
Study: 30082073

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg daily
Number of subjects: 2298

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 2298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2298
Study: 26730716

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day)
Number of subjects: 87
Study: 24885673

Group type: EXPERIMENTAL
Intervention: Dader Method of pharmaceutical care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care and verbal-written counseling regarding BD
Number of subjects: 0
Study: 22273548

Group type: EXPERIMENTAL
Intervention: Threatening information regarding the heat stimulus
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High levels of parental catastrophizing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Neutral information regarding the heat stimulus
Number of subjects: 56
Study: 21418281

Group type: EXPERIMENTAL
Intervention: Topical 3% diclofenac sodium plus hyaluronan (DFS) gel, twice daily for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod (IMQ) cream, twice per week for 16 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Base cream (BC), twice daily for 12 weeks
Number of subjects: 61
Study: 16810714

Group type: EXPERIMENTAL
Intervention: Wald test with intra-subject variability
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LRT with intra-subject variability
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wald test for bioequivalence trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tenofovir treatment
Number of subjects: 12
Study: 15643103

Group type: EXPERIMENTAL
Intervention: Gepirone ER (20 mg/d titrated to 40 to 80 mg/d)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 420
Study: 12224305

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 99Tc-MDP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents and 99Tc-MDP
Number of subjects: 66
Study: 10428516

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 0.1 mL sterile water
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of 0.5 mL sterile water
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study: 7763029

Group type: EXPERIMENTAL
Intervention: FEC regimen (Epirubicin, Fluorouracil, Cyclophosphamide)
Number of subjects: 158

Group type: COMPARATOR
Intervention: FNC regimen (Mitoxantrone, Fluorouracil, Cyclophosphamide)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 158

Group type: COMPARATOR
Intervention: FNC regimen
Number of subjects: 158
Study: 1969982

Group type: EXPERIMENTAL
Intervention: CGRP infusion at progressively increased concentrations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study: 393571

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Benzilonium (anticholinergic, 70 micrograms/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine (30 micrograms/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine (50 micrograms/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 20
Study: 31805973

Group type: EXPERIMENTAL
Intervention: Enhanced Go NAPSACC
Number of subjects: 485

Group type: COMPARATOR
Intervention: Basic Go NAPSACC
Number of subjects: 485
Study: 28775942

Group type: EXPERIMENTAL
Intervention: Physician's advice with standard counselling
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard counselling alone
Number of subjects: 160
Study: 25850390

Group type: EXPERIMENTAL
Intervention: Zero-P spacer (group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Anterior cervical plate and interbody cage (group B)
Number of subjects: 69
Study: 23298192

Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet (30% inclusion, 0.45% available phosphorus)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet (30% inclusion, 0.3% available phosphorus)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low phosphorus diet (0.3% available phosphorus)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet
Number of subjects: 180

Group type: COMPARATOR
Intervention: Normal pea diet
Number of subjects: 180

Group type: COMPARATOR
Intervention: Soybean meal diet
Number of subjects: 180
Study: 20659260

Group type: EXPERIMENTAL
Intervention: SB12® (0.025% chlorhexidine and 0.3% zinc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listerine®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BreathRx®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SmartMouth®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LacerFresh®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 0
Study: 19075055

Group type: EXPERIMENTAL
Intervention: aplaviroc plus lamivudine-zidovudine (Combivir)
Number of subjects: 8
Study: 17321923

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 10 mg of hyperbaric 1% lidocaine (L group, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia with fentanyl 1 microg.kg‐1 IV and 1.0 mg.kg‐1 propofol (F/P group, n=40)
Number of subjects: 80
Study: 15646652

Group type: EXPERIMENTAL
Intervention: Ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ferric iron polysaccharide complex (Niferex, ferro‐glycine sulfate) plus ascorbic acid
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 72
Study: 11468148

Group type: EXPERIMENTAL
Intervention: Cytarabine alone
Number of subjects: 388

Group type: COMPARATOR
Intervention: Cytarabine and mitoxantrone
Number of subjects: 388
Study: 9886204

Group type: EXPERIMENTAL
Intervention: Home chlorination intervention
Number of subjects: 1583

Group type: COMPARATOR
Intervention: No piped water (control group)
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Piped water (control group)
Number of subjects: 1583
Study: 8092577

Group type: EXPERIMENTAL
Intervention: 4 min of 100% O2 (Group A, n = 12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 4 maximally deep inspirations of 100% O2 (Group B, n = 15)
Number of subjects: 27
Study: 3139571

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg mixed testosterone esters at 2-week intervals
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 120 mg bd
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone pellets (6 x 100 mg)
Number of subjects: 15
Study: 30204486

Group type: EXPERIMENTAL
Intervention: Medtronic HCL with enhancements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medtronic standard HCL algorithm (Control)
Number of subjects: 12
Study: 28126447

Group type: EXPERIMENTAL
Intervention: TT-173
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 26214071

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with GBNs (13 g/day for three months)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 23356951

Group type: EXPERIMENTAL
Intervention: Virtual reality‐based vocational training group (VRG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Virtual reality‐based vocational training group (VRG) and therapist‐administered group (TAG)
Number of subjects: 95
Study: 21679171

Group type: EXPERIMENTAL
Intervention: Foster care placement by 15 months
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Foster care placement from 15 to 24 months
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Foster care placement after 24 months
Number of subjects: 174
Study: 18299865

Group type: EXPERIMENTAL
Intervention: Candida albicans
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis
Number of subjects: 1073
Study: 16958945

Group type: EXPERIMENTAL
Intervention: SSRI‐assisted BDZ‐reduction group (10‐20 mg of paroxetine, n = 22)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Simple BDZ‐reduction group (no paroxetine, n = 23)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Reference group (no BDZ‐reduction, n = 21)
Number of subjects: 66